{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:19:05Z","timestamp":1778289545977,"version":"3.51.4"},"reference-count":38,"publisher":"American Diabetes Association","issue":"4","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:p>OBJECTIVE\u2014The aim of this study was to provide a comprehensive meta-analysis of randomized controlled clinical studies on the effects of sibutramine on weight loss and glycemic control in obese subjects with type 2 diabetes.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014Controlled clinical trials assessing the effect sizes of sibutramine on weight loss effects on glycemia in obese subjects with type 2 diabetes were identified and reviewed using the Cochrane Library, Medline, EMBASE, and a manual search.<\/jats:p>\n               <jats:p>RESULTS\u2014Eight placebo-controlled, double-blind, randomized trials of sibutramine were included. After sibutramine treatment, the decrease in body weight and waist circumference was significantly greater than in the placebo group. Fasting blood glucose and HbA1c significantly decreased after sibutramine treatment. Treatment benefits were seen in plasma triglycerides and HDL, without significant variations in serum total and LDL cholesterol. No differences in systolic blood pressure between the sibutramine and the placebo groups were seen, while recording of diastolic blood pressure and heart rate showed that sibutramine produced a small increase relative to placebo.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014A pharmacological approach in a weight management program for patients with type 2 diabetes may be helpful in glycemic control and in the management of other risk factors. Sibutramine may help improve glucose control because it is conducive to weight loss. The reviewed data on the effect of sibutramine further enforce the recommendations that weight management may be the most important therapeutic task for most obese subjects with type 2 diabetes.<\/jats:p>","DOI":"10.2337\/diacare.28.4.942","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"942-949","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":73,"title":["Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes"],"prefix":"10.2337","volume":"28","author":[{"given":"Roberto","family":"Vettor","sequence":"first","affiliation":[{"name":"From the Department of Medical and Surgical Sciences, Endocrine-Metabolic Laboratory, Internal Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Serra","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Surgical Sciences, Endocrine-Metabolic Laboratory, Internal Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Fabris","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Surgical Sciences, Endocrine-Metabolic Laboratory, Internal Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Pagano","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Surgical Sciences, Endocrine-Metabolic Laboratory, Internal Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Federspil","sequence":"additional","affiliation":[{"name":"From the Department of Medical and Surgical Sciences, Endocrine-Metabolic Laboratory, Internal Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"key":"2022031216145486100_R1","doi-asserted-by":"crossref","unstructured":"Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999\u20132002. JAMA\u2008291: 2847\u20132850, 2004","DOI":"10.1001\/jama.291.23.2847"},{"key":"2022031216145486100_R2","doi-asserted-by":"crossref","unstructured":"Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA\u2008287:356\u2013359, 2002","DOI":"10.1001\/jama.287.3.356"},{"key":"2022031216145486100_R3","doi-asserted-by":"crossref","unstructured":"Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, the DECODE Study Group: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med\u2008164:1066\u20131076, 2004","DOI":"10.1001\/archinte.164.10.1066"},{"key":"2022031216145486100_R4","doi-asserted-by":"crossref","unstructured":"Shaughnessy AF, Slawson DC: What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes (Review). BMJ\u2008327:266, 2003","DOI":"10.1136\/bmj.327.7409.266"},{"key":"2022031216145486100_R5","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031216145486100_R6","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet\u2008352:854\u2013865, 1998","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2022031216145486100_R7","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ\u2008317:703\u2013713, 1998","DOI":"10.1136\/bmj.317.7160.703"},{"key":"2022031216145486100_R8","doi-asserted-by":"crossref","unstructured":"Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol\u200851:1235\u20131241, 1998","DOI":"10.1016\/S0895-4356(98)00131-0"},{"key":"2022031216145486100_R9","unstructured":"Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. Harcourt Brace Janovich, ed. Orlando, FL, Academic Press, 1985"},{"key":"2022031216145486100_R10","doi-asserted-by":"crossref","unstructured":"Serrano-Rios M, Melchionda N, Moreno-Carretero E, the Spanish Investigators: Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med\u200819:119\u2013124, 2002","DOI":"10.1046\/j.1464-5491.2002.00655.x"},{"key":"2022031216145486100_R11","doi-asserted-by":"crossref","unstructured":"McNulty SJ, Ur E, Williams G, the Multicenter Sibutramine Study Group: A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care\u200826:125\u2013131, 2003","DOI":"10.2337\/diacare.26.1.125"},{"key":"2022031216145486100_R12","doi-asserted-by":"crossref","unstructured":"Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, the Sibutramine\/Diabetes Clinical Study Group: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab\u20082:175\u2013187, 2000","DOI":"10.1046\/j.1463-1326.2000.00081.x"},{"key":"2022031216145486100_R13","doi-asserted-by":"crossref","unstructured":"Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab\u20082:105\u2013112, 2000","DOI":"10.1046\/j.1463-1326.2000.00071.x"},{"key":"2022031216145486100_R14","doi-asserted-by":"crossref","unstructured":"Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N: Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care\u200824:1957\u20131960, 2001","DOI":"10.2337\/diacare.24.11.1957"},{"key":"2022031216145486100_R15","doi-asserted-by":"crossref","unstructured":"Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A: Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther\u200826:1427\u20131435, 2004","DOI":"10.1016\/j.clinthera.2004.09.017"},{"key":"2022031216145486100_R16","doi-asserted-by":"crossref","unstructured":"Kaukua JK, Pekkarinen TA, Rissanen AM: Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord\u200828:600\u2013605, 2004","DOI":"10.1038\/sj.ijo.0802591"},{"key":"2022031216145486100_R17","doi-asserted-by":"crossref","unstructured":"Redmon JB, Raatz SK, Reck KP, Swanson JE, Kwong CA, Fan Q, Thomas W, Bantle JP: One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care\u200826:2505\u20132511, 2003","DOI":"10.2337\/diacare.26.9.2505"},{"key":"2022031216145486100_R18","doi-asserted-by":"crossref","unstructured":"Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab\u200889:2595\u20132600, 2004","DOI":"10.1210\/jc.2004-0372"},{"key":"2022031216145486100_R19","doi-asserted-by":"crossref","unstructured":"Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab\u200889:2583\u20132589, 2004","DOI":"10.1210\/jc.2004-0535"},{"key":"2022031216145486100_R20","doi-asserted-by":"crossref","unstructured":"Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet\u2008336:129\u2013133, 1990","DOI":"10.1016\/0140-6736(90)91656-U"},{"key":"2022031216145486100_R21","doi-asserted-by":"crossref","unstructured":"Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J: Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med\u2008164:1395\u20131404, 2004","DOI":"10.1001\/archinte.164.13.1395"},{"key":"2022031216145486100_R22","doi-asserted-by":"crossref","unstructured":"James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight maintenance after weight loss: a randomised trial: STORM Study Group: Sibutramine Trial of Obesity Reduction and Maintenance. Lancet\u2008356:2119\u20132125, 2000","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"2022031216145486100_R23","doi-asserted-by":"crossref","unstructured":"Glazer G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med\u2008161:1814\u20131824, 2001","DOI":"10.1001\/archinte.161.15.1814"},{"key":"2022031216145486100_R24","doi-asserted-by":"crossref","unstructured":"Wirth A, Krause J: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA\u2008286:1331\u20131339, 2001","DOI":"10.1001\/jama.286.11.1331"},{"key":"2022031216145486100_R25","doi-asserted-by":"crossref","unstructured":"Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of Hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med\u2008141:413\u2013420, 2004","DOI":"10.7326\/0003-4819-141-6-200409210-00006"},{"key":"2022031216145486100_R26","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet\u2008352:837\u2013853, 1998","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2022031216145486100_R27","doi-asserted-by":"crossref","unstructured":"Libby P, Plutzky J: Diabetic macrovascular disease: the glucose paradox? Circulation\u2008106:2760\u20132763, 2002","DOI":"10.1161\/01.CIR.0000037282.92395.AE"},{"key":"2022031216145486100_R28","doi-asserted-by":"crossref","unstructured":"Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation\u2008104:3046\u20133051, 2001","DOI":"10.1161\/hc5001.100624"},{"key":"2022031216145486100_R29","doi-asserted-by":"crossref","unstructured":"Geiss LS, Rolka DB, Engelgau MM: Elevated blood pressure among U.S. adults with diabetes, 1988\u20131994. Am J Prev Med\u200822:42\u201348, 2002","DOI":"10.1016\/S0749-3797(01)00399-3"},{"key":"2022031216145486100_R30","doi-asserted-by":"crossref","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA\u2008289:2560\u20132572, 2003","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"2022031216145486100_R31","doi-asserted-by":"crossref","unstructured":"Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB: Sibutramine produces dose-related weight loss. Obes Res\u20087:189\u2013198, 1999","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"2022031216145486100_R32","doi-asserted-by":"crossref","unstructured":"McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med\u2008160:2185\u20132191, 2000","DOI":"10.1001\/archinte.160.14.2185"},{"key":"2022031216145486100_R33","doi-asserted-by":"crossref","unstructured":"McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, the Sibutramine in Hypertensives Clinical Study Group: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens\u200816:5\u201311, 2002","DOI":"10.1038\/sj.jhh.1001298"},{"key":"2022031216145486100_R34","doi-asserted-by":"crossref","unstructured":"Hazenberg BP: Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology\u200894:152\u2013158, 2000","DOI":"10.1159\/000047310"},{"key":"2022031216145486100_R35","doi-asserted-by":"crossref","unstructured":"Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P: Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J\u2008144:508\u2013515, 2002","DOI":"10.1067\/mhj.2002.124403"},{"key":"2022031216145486100_R36","doi-asserted-by":"crossref","unstructured":"Kim SH, Lee YM, Jee SH, Nam CM: Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res\u200811:1116\u20131123, 2003","DOI":"10.1038\/oby.2003.152"},{"key":"2022031216145486100_R37","doi-asserted-by":"crossref","unstructured":"Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation\u2008106:2459, 2002","DOI":"10.1161\/01.CIR.0000036370.31856.73"},{"key":"2022031216145486100_R38","doi-asserted-by":"crossref","unstructured":"Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G: Sympathetic activation in obese normotensive subjects. Hypertension\u200825:560\u2013563, 1995","DOI":"10.1161\/01.HYP.25.4.560"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/28\/4\/942\/566507\/zdc00405000942.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/28\/4\/942\/566507\/zdc00405000942.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T16:38:19Z","timestamp":1647103099000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/28\/4\/942\/23704\/Effect-of-Sibutramine-on-Weight-Management-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.28.4.942","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}